Nucleic Acids Research, 2003, Vol. 31, No. 16 4929-4940
© 2003 Oxford University Press
An important role for RUNX3 in human L1 transcription and retrotransposition
Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA and 1 Center for Research on Reproduction and Womens Health, University of Pennsylvania, Philadelphia, PA 19104, USA
*To whom correspondence should be addressed. Tel: +1 215 898 3582; Fax: +1 215 573 7760; Email: kazazian{at}mail.med.upenn.edu
LINE-1s (long interspersed nuclear elements-1) are abundant non-LTR retrotransposons that comprise 17% of the human genome. The 5' untranslated region (5'UTR) of human L1 (L1Hs) houses a poorly understood internal promoter. Here we report that mutations at a putative runt-domain transcription factor (RUNX) site (+83 to +101) in the 5'UTR decreased L1Hs transcription and retrotransposition in cell culture-based assays. Exogenous expression of RUNX3, but not the other two RUNX family members, RUNX1 and RUNX2, increased L1Hs transcription and retrotransposition, which were otherwise decreased by siRNAs targeting RUNX3 and a dominant negative RUNX. Further more, the specific interaction between RUNX3 and its binding site was demonstrated by an electrophoretic mobility shift assay (EMSA) using an anti-RUNX3 antibody. Interestingly, RUNX3 may also regulate the antisense promoter activity of L1Hs 5'UTR via another putative RUNX site (+526 to +508), as revealed by site-directed mutations and exogenous expression of RUNX factors. Our results indicate an important role for RUNX3 in L1Hs retrotransposition as well as transcription from its 5'UTR in both sense and antisense directions, and they should contribute to our understanding of the mechanism underlying L1Hs retrotransposition and its impact on the expression of adjacent cellular genes.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
V. P. Belancio, D. J. Hedges, and P. Deininger Mammalian non-LTR retrotransposons: For better or worse, in sickness and in health Genome Res., March 1, 2008; 18(3): 343 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Muckenfuss, M. Hamdorf, U. Held, M. Perkovic, J. Lower, K. Cichutek, E. Flory, G. G. Schumann, and C. Munk APOBEC3 Proteins Inhibit Human LINE-1 Retrotransposition J. Biol. Chem., August 4, 2006; 281(31): 22161 - 22172. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. d. C. Seleme, M. R. Vetter, R. Cordaux, L. Bastone, M. A. Batzer, and H. H. Kazazian Jr. Extensive individual variation in L1 retrotransposition capability contributes to human genetic diversity PNAS, April 25, 2006; 103(17): 6611 - 6616. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. P. Belancio, D. J. Hedges, and P. Deininger LINE-1 RNA splicing and influences on mammalian gene expression Nucleic Acids Res., March 22, 2006; 34(5): 1512 - 1521. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Khan, A. Smit, and S. Boissinot Molecular evolution and tempo of amplification of human LINE-1 retrotransposons since the origin of primates Genome Res., January 1, 2006; 16(1): 78 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yang, L. Zhang, and H. H. Kazazian Jr L1 retrotransposon-mediated stable gene silencing Nucleic Acids Res., March 30, 2005; 33(6): e57 - e57. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Soifer, A. Zaragoza, M. Peyvan, M. A. Behlke, and J. J. Rossi A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon Nucleic Acids Res., February 8, 2005; 33(3): 846 - 856. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lavie, E. Maldener, B. Brouha, E. U. Meese, and J. Mayer The human L1 promoter: Variable transcription initiation sites and a major impact of upstream flanking sequence on promoter activity Genome Res., November 1, 2004; 14(11): 2253 - 2260. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Athanikar, R. M. Badge, and J. V. Moran A YY1-binding site is required for accurate human LINE-1 transcription initiation Nucleic Acids Res., July 22, 2004; 32(13): 3846 - 3855. [Abstract] [Full Text] [PDF] |
||||



